Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CCI-001

Phase 1Small molecule

PPharmaMatrix Holdings Ltd

CCI-001 is one of 16 small molecule programs targeting Solid Tumours. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

15

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumoursRecruiting

Solid TumoursPhase 1

Recruiting

Competition

Competitive Landscape

27 competitors in Solid Tumours

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Imfinzi

Gemzar

Johnson & Johnson

Abraxane

Bristol-Myers Squibb

Hernexeos

Boehringer Ingelheim

Adriamycin

Cetrelimab

Johnson & Johnson

HMBD-001

HHummingbird Bioscience

AZD0171

Dose Expansion

PPeking University

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Solid Tumours

NCT04823897

Clinical

Trials by Indication[1]

Solid Tumours1 trial

A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours

Recruiting·PPharmaMatrix Holdings Ltd·Phase 1·NCT04823897·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CCI-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CCI-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CCI-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PharmaMatrix Holdings Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPharmaMatrix Holdings Ltd

Related News